Table 1.
A review of the 127 cases: All the studies were of level of evidence 5.
| Ref. | Cases/sex | Age (years) | Cell type | Treatment | Outcome |
|---|---|---|---|---|---|
| [1] | 1/M | 4 | High-grade (grade 3), muscle-invasive | TURBT, R after 3 months, | NR at 6 months |
| Papillary UC, stage T2b | Partial cystectomy + chemo | ||||
| [2] | 6/4M/2F | 6–17 | Grade I TCC | TURBT | NR |
| [3] | 8/6M/2F | <18 | Two G1Ta, 1 G1T1, 1 G2T1, and 5 G2Ta | TURBT | NR 8–27 years |
| [4] | 1/M | 10 | Grade I well-differentiated | TURBT | Pending |
| [5] | 12/M | <21 | Low-grade/low-stage | TURBT | 1 patient had 1 R |
| [6] | 1/F | 9 | Grade 1 TCC | TURBT | N/A |
| [7] | 5/M | 11–18 | Low-grade | TURBT | N/A |
| [8] | 7/M + F | <16 | Low-grade | TURBT | NR after 18 months |
| [9] | 1/M | 5 | High-grade | Partial cystectomy | NR after 1 year |
| [10] | 1/F | 16 | High-grade invasive TCC | Radio- and chemotherapy | Died from metastatic disease |
| [12] | 1/F | 9 | Low-grade | TURBT | NR in 4 years |
| [13] | 2/M/F | 15/18 | Superficial TCC | TURBT | N/A |
| [14] | 2/F | 8/9 | Grade 1 stage pTa | TURBT | NR in 4 years |
| [15] | 1/F | 12 | Superficial TCC | TURBT | N/A |
| [16] | 1/M | 10 | Grade 2 TCC with lamina propria invasion | TURBT + Mitomycin | N/A |
| [17] | 1/F | 10 | PUNLMP | TURBT | NR in 9 months |
| [18] | 23/19M/4F | 4–20 | 2 papilloma, 10 PUNLMP, 8 low grade, | TURBT | 3 R in 13 years |
| 3 high grade | |||||
| [19] | 1/M | 12 | Ta grade II | TURBT | NR in 2 months |
| [20] | 1/M | 13 | Low grade | TURBT | N/A |
| [21] | 1/F | 10 | Grade I papillary TCC | TURBT | R in 2 years |
| [22] | 1/M | 18 | Grade 1 TCC | TURBT | NR in 2 years |
| [24] | 2/M | <20 | Grade 1 and 2 | TURBT | N/A |
| [25] | 1/M | 8 | Grade I superficial (pTa) | TURBT | NR in 5 years |
| [26] | 2/M | <10 | Low-grade | TURBT | N/A |
| [27] | 6/4M/2F | 10–22 | Low-grade and low-stage | TURBT | N/A |
| [28] | 1/M | 8 | Papillary TCC with lymphangiectasia | TURBT | N/A |
| [29] | 1/M | 11 | Low-grade | TURBT | N/A |
| [30] | 1/M | 13 | Low-grade | TURBT | N/A |
| [32] | 1/F | 8 | Grade 1 TCC | TURBT | N/A |
| [33] | 7/M | <20 | Low-grade | TURBT | NR |
| [34] | 1/M | 14 | Papillary noninvasive TCC | TURBT | N/A |
| [35] | 3/M | < 18 | Low-grade | TURBT | Two R |
| [37] | 1/M | <18 | Grade II to III + submucosal invasion | TURBT | NR in 30 months |
| [38] | 1/F | 10 | Papillary carcinoma | TURBT | N/A |
| [40] | 1/M | 16 | Grade I–II | TURBT | NR in 2 years |
| [41] | 2/M | 2–3 | Papillary epithelial tumours | TURBT | N/A |
| [45] | 1/M | 11 | Papillary TCC | TURBT | N/A |
| [46] | 8/5M/3F | 10–20 | Low-grade | TURBT | NR in 7 years |
| [47] | 1/M | <18 | Low-grade | TURBT | N/A |
| [50] | 1/M | 10 | Grade 1, noninvasive TCC | TURBT | NR in 2 years |
| [52] | 2/M | <18 | Low-grade | TURBT | 1 R |
| [53] | 4/2F/2M | 2–18 | Low-grade TCC | TURBT | NR at 3/6/4/1.5 years |
| [54] | 1/F | 16 | Papillary TCC, grade I/Costello syndrome | TURBT | NR in 2 years |
| Present | 2/M | 5–12 | Low-grade, 1 PUNLMP | TURBT | NR in 3 years |